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T
he recently published NICE guideline MI: secondary preven-
tion in primary and secondary care for patients following a
myocardial infarction1 updates the previous guideline pub-
lished in 20012 and the relevant sections of the National Service
Framework for coronary heart disease.3 The guideline is important
to clinicians in both primary and secondary care, and to those
who plan services. There have been significant improvements in
recent years and the majority of eligible patients leaving
hospital after an acute myocardial infarction are now treated
with aspirin and statins. However, other important interven-
tions such as advice about lifestyle and cardiac rehabilitation
are less consistently provided and there is inconsistent practice
with regards to some drug therapies. This guideline makes
recommendations for lifestyle and cardiac rehabilitation in far
greater detail than in the previous one, as well as updating and
expanding the recommendations for drug treatment.
Patients who have just had an acute myocardial infarction are
readily identifiable, and this guideline addresses secondary
prevention after the very early acute phase. It also makes
recommendations for the management of patients with a proven
myocardial infarction in the past. These patients will generally no
longer be under hospital follow-up and it will be the responsi-
bility of primary care to review patients on their disease registers
to ensure that management has been optimised.
DRUG TREATMENT
The recommendations that aspirin, beta blockers, statin and ACE
inhibitors be considered in all patients after acute myocardial
infarction are maintained in this guideline and further supple-
mented to include appropriate treatment with a combination of
aspirin and clopidogrel, and early treatment with an aldosterone
antagonist in patients with heart failure. Other drugs such as
vitamin K antagonists are also now included.
Recommendations for treatment with the combination of
aspirin and clopidogrel in non-ST elevation myocardial infarction
restate those of the NICE technology appraisal number 80,
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary
syndrome,4 to continue treatment for a year. After an ST elevation
myocardial infarction patients who have been thrombolysed and
treated with clopidogrel and aspirin on initial presentation should
continue with both agents for at least four weeks. However,
evidence is lacking as to the optimal duration of treatment with
both agents in patients after an ST elevation myocardial infarction
and, in practice, clinicians in secondary care should make explicit
recommendations for the duration of dual antiplatelet therapy as
part of the patient management plan. Further research to examine
the optimal duration of dual antiplatelet therapy in this group is
recommended in the guideline.
Treatment with both aspirin and clopidogrel is not routinely
recommended for longer than a year. Treatment plans can be
made in secondary care, but most patients who have had a
myocardial infarction will no longer be under hospital follow-up
one year later. Primary care will need to make sure that patients
have an individual review before stopping clopidogrel to ensure
that other indications to continue both agents have not developed.
Patients with heart failure after myocardial infarction are at
high risk for further events and early treatment (within 3–
14 days) with an aldosterone antagonist licensed for this
indication is recommended in patients who have had symptoms
and signs of heart failure and a left ventricular ejection fraction
of 40% or less, preferably after an ACE inhibitor. This means
that all patients with heart failure after acute myocardial
infarction will require an early assessment of left ventricular
function, generally before discharge, so that appropriate
treatment can be initiated in those fulfilling the criteria. This
may prove a challenge for some units and services should
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consider how they will implement this recommendation. It is
unknown if treatment with a non-selective aldosterone
antagonist will be as efficacious as a selective aldosterone
receptor antagonist licensed for this indication; this has been
identified as a recommendation for further research.
All patients treated with ACE inhibitors require monitoring
of serum potassium and renal function, and those also treated
with an aldosterone antagonist require particularly careful
monitoring. Secondary prevention measures after acute myo-
cardial infarction will generally be initiated in hospital, but it
will not be possible to up-titrate treatment in all patients to
optimum doses before discharge. Effective and explicit early
communication of a treatment plan between secondary care
and primary care, which is shared with the patient, will help
ensure that patients have their treatment optimised and
monitored in a safe and timely manner. Patients need
consistent and accurate information and to have their treat-
ment explained. This should include their need for monitoring
and dose titration of drug treatment.
After myocardial infarction, some patients have other
indications for anticoagulation and are treated with warfarin.
This guideline addresses whether antiplatelet agents should
also be considered in such patients. The addition of aspirin
should be considered in those treated with moderate intensity
warfarin who have a low risk of bleeding complications. In
practice the management of patients treated with warfarin will
require a careful assessment of the indications for warfarin and
the importance of continuing it, the level of individual patient
cardiovascular risk and bleeding risk and their own wishes, as
well as taking into account other indications for antiplatelet
agents such as recent coronary stenting.
This guideline recommends that after myocardial infarction all
patients are treated with a statin as soon as possible. However,
clinicians may be disappointed that recommendations about the
intensity of statin treatment and cholesterol lowering have not
been made. This was considered by the guideline group, but it
was agreed that separate recommendations on these important
issues in isolation from recommendations for management of
patients with other expressions of coronary heart disease and
other vascular diseases should be avoided. Recommendations for
the intensity of statin treatment and cholesterol lowering in
patients with vascular disease, including those after myocardial
infarction, are being addressed by the ongoing NICE lipid
modification guideline Cardiovascular risk assessment: the modifica-
tion of blood lipids for the primary and secondary prevention of
cardiovascular disease, due to be published in January 2008.5
Secondary prevention is for life. The guideline makes it clear
whether or not any drug treatments should be routinely
discontinued. However, some patients may wish to review the
benefits of long-term treatment—particularly those who,
following a comprehensive cardiological assessment, are at
low risk of further events. In one study6 of patients with stable
coronary disease with preserved left ventricular function,
including 55% with a history of myocardial infarction, the
annualised rate of death from all causes was only 1.6%, similar
to that of an age- and sex-matched general population, and the
addition of ACE inhibitors conferred no additional risk
reduction in cardiovascular mortality, myocardial infarction or
coronary revascularisation. There was insufficient evidence for
this guideline to recommend a subgroup of patients who
routinely should not continue all long-term drug treatment.
However, patients may wish to review the long-term benefit of
selected drugs, requiring a careful assessment and discussion of
each patient’s wishes and how well the drugs are tolerated,
balanced against the size of benefit with regards to risk
reduction. Such decisions should be clearly documented and
communicated between secondary and primary care. It is
unclear if there is a time interval following which any such
decisions should routinely be revisited in case of disease
progression, but it is intuitive that at a minimum this should
occur promptly if any new cardiac symptoms develop or if new
indications for treatment occur. The importance of these issues
is recognised as an area requiring further research.
CARDIAC REHABILITATION AND LIFESTYLE
Drug therapy has a key role for secondary prevention after
myocardial infarction, but equally important are the recommenda-
tions for lifestyle and cardiac rehabilitation. Published evidence for
cardiac rehabilitation has been supplemented by additional
analyses of its cost effectiveness and methods used to increase
uptake to meet the recommendations. Details of these are readily
available in the full version of the guideline.7 Cardiac rehabilitation
is a clinical and cost effective intervention after acute myocardial
infarction. All patients should be offered a comprehensive cardiac
rehabilitation programme which includes an exercise component
tailored to individual needs, and those with left ventricular
dysfunction should not routinely be excluded. Programmes should
also include educational and stress management components, but
complex psychological interventions such as cognitive behavioural
therapy are not routinely recommended. Information should be
accurate and consistent, and include advice about returning to
work and everyday activities. The need to address issues regarding
sexual activity is emphasised. Further recommendations address
the importance of providing services which are accessible and
acceptable, and which meet the needs of all patients, including
those least likely to access rehabilitation. Cardiac rehabilitation
starts before discharge from hospital, but is largely provided after
discharge and services provided in secondary care and the
community must be integrated. Some patients may prefer a
home-based programme and services may offer such a programme
validated for patients after myocardial infarction.
All health professionals should encourage patients to join a
cardiac rehabilitation programme and senior medical staff should
include cardiac rehabilitation when they are discussing and
planning secondary prevention measures with patients. A survey
in 2000 estimated that between 14% and 23% of patients were
enrolled into cardiac rehabilitation programmes after myocardial
infarction.8 Services have developed since this survey, but there is
still wide disparity between geographical areas in access and
uptake to cardiac rehabilitation, and it is recognised that access
may be particularly poor by patients in selected groups. Clinicians
and commissioners will need to work together to make sure the
recommendations are implemented. The NICE costing tool can be
used to help estimate additional costs.9
Gaps in the evidence for cardiac rehabilitation emerged
during development of the guideline and recommendations are
made for these to be addressed. Further research is needed to
examine the most effective strategies to promote uptake and
adherence to comprehensive cardiac rehabilitation, the efficacy
of the non-exercise components of the rehabilitation pro-
grammes, and which are the most effective strategies for
maintaining exercise and dietary changes.
This guideline has made clear recommendations for lifestyle
changes and supports healthcare professionals in providing
consistent and coherent messages. Advice about both diet and
physical activity is enhanced by discussion of patients’ past and
current habits before discussing and advising any changes. For
patients who have had an acute MI, this should be integrated
with cardiac rehabilitation. Primary care services have a key
role to review and discuss lifestyle factors as part of the ongoing
long-term education and support of patients.
Patients should be advised to have a Mediterranean-style diet
and to consume 7 g of omega-3 fatty acids per week from 2–4
portions of oily fish. Those within three months of an acute
h l
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myocardial infarction who are not achieving 7 g of omega-3 fatty
acids per week should be considered for 1 g daily of omega-3 acid
ethyl esters treatment licensed for secondary prevention post
myocardial infarction for up to four years. However, there is
uncertainty about the efficacy of omega-3 acid ethyl esters
supplements initiated later after myocardial infarction and
further research is required. The guideline makes important
recommendations about other supplements which some patients
may consider taking, and will help ensure that patients receive
accurate information. There is no evidence that antioxidant
supplements and folic acid will reduce cardiovascular risk in
patients after myocardial infarction, and beta carotene supple-
ments should be avoided as they may be harmful.
The importance of undertaking regular physical activity to
increase exercise capacity is emphasised. Heart rate monitoring
is not recommended, as many patients are treated with beta
blockers. However, patients should aim to build up their
exercise and aim for 20–30 min of physical activity per day to
the point that they are slightly breathless. For those after acute
myocardial infarction, exercise will be part of the cardiac
rehabilitation programme, but all clinicians should emphasise
the importance of continuing this long term.
It will be no surprise that patients who smoke should be
advised to quit and offered the assistance of a smoking
cessation service. Reference is made to other published NICE
guidance for this10 11 and also for weight management.12
CARDIOLOGICAL ASSESSMENT
Patients who have not been considered for coronary revascu-
larisation during the acute phase require further cardiological
assessment to identify those who will benefit from revascular-
isation for secondary prevention, taking into account comor-
bidity. It was beyond the scope of the guideline to recommend
how best that assessment be made, but will include looking for
evidence of reversible myocardial ischaemia, the extent of
coronary artery disease and left ventricular function. Patients
who have left ventricular systolic dysfunction should also be
considered for an implantable cardioverter defibrillator in line
with the recommendations in the NICE technology appraisal
number 95, Implantable cardioverter defibrillators (ICDs) for the
treatment of arrhythmias.13
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